Differentiated thyroid cancer

Cover Page

Cite item

Full Text

Abstract

Differentiated thyroid cancer

About the authors

Dmitrii G. Bel’tsevich

National Medical Research Center of Endocrinology

Author for correspondence.
Email: belts67@gmail.com
ORCID iD: 0000-0001-7098-4584
SPIN-code: 4475-6327

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Ali M. Mudunov

Clinical Hospital "Lapino"

Email: ali.mudunov@info.ru
ORCID iD: 0000-0002-0918-3857
SPIN-code: 3516-6616

D. Sci. (Med.), Prof. RAS

Russian Federation, Moscow

Vladimir E. Vanushko

National Medical Research Center of Endocrinology

Email: vanushko@gmail.com
ORCID iD: 0000-0001-6338-7490
SPIN-code: 6097-8990

D. Sci. (Med.)

Russian Federation, Moscow

Pavel O. Rumiantsev

National Medical Research Center of Endocrinology

Email: pavelrum@gmail.com
ORCID iD: 0000-0002-7721-634X
SPIN-code: 7085-7976

D. Sci. (Med.)

Russian Federation, Moscow

Galina A. Mel’nichenko

National Medical Research Center of Endocrinology

Email: teofrast2000@mail.ru
ORCID iD: 0000-0002-5634-7877
SPIN-code: 8615-0038

D. Sci. (Med.), Prof., Acad. RAS

Russian Federation, Moscow

Nikolai S. Kuznetsov

National Medical Research Center of Endocrinology

Email: kuznetsovnikolays@yandex.ru
SPIN-code: 8412-1098

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Sergei O. Podvyaznikov

Russian Medical Academy of Continuous Professional Education

Email: podvs@inbox.ru
ORCID iD: 0000-0003-1341-0765
SPIN-code: 7353-1895

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Yuri V. Alymov

Blokhin National Medical Research Center of Oncology

Email: allmedperevod@gmail.com
ORCID iD: 0000-0002-6851-9867

Cand. Sci. (Med.)

Russian Federation, Moscow

Andrei P. Poliakov

Herzen Moscow Research Institute of Oncology – branch of the National Medical Research Center for Radiology

Email: appolyakov@mail.ru
ORCID iD: 0000-0002-5894-1917

D. Sci. (Med.), Herzen Moscow Research Institute of Oncology – branch of the National Medical Research Center for Radiology

Russian Federation, Moscow

Valentin V. Fadeev

Sechenov First Moscow State Medical University (Sechenov University)

Email: walfad@mail.ru
ORCID iD: 0000-0002-3026-6315
SPIN-code: 6825-8417

Corr. Memb. RAS, D. Sci. (Med.), Prof.

Russian Federation, Moscow

Mikhail V. Bolotin

Blokhin National Medical Research Center of Oncology

Email: walfad@mail.ru

Cand. Sci. (Med.)

Russian Federation, Moscow

Feliks E. Sevriukov

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: walfad@mail.ru

department head

Russian Federation, Obninsk

Valerii V. Krylov

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: walfad@mail.ru

D. Sci. (Med.)

Russian Federation, Obninsk

Aleksandr A. Fedenko

Herzen Moscow Research Institute of Oncology – branch of the National Medical Research Center for Radiology

Email: walfad@mail.ru

department head

Russian Federation, Moscow

Larisa V. Bolotina

Blokhin National Medical Research Center of Oncology

Email: walfad@mail.ru
ORCID iD: 0000-0003-4879-2687

D. Sci. (Med.)

Russian Federation, Moscow

Andrei A. Zharov

Blokhin National Medical Research Center of Oncology

Email: walfad@mail.ru

pathologist

Russian Federation, Moscow

Natalia A. Falaleeva

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: walfad@mail.ru

D. Sci. (Med.), Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Russian Federation, Obninsk

Elena V. Filonenko

Herzen Moscow Research Institute of Oncology – branch of the National Medical Research Center for Radiology

Email: walfad@mail.ru

Head of Herzen Moscow Research Institute of Oncology – branch of the National Medical Research Center for Radiology

Russian Federation, Moscow

Aleksei A. Nevol’skikh

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: walfad@mail.ru

D. Sci. (Med.)

Russian Federation, Obninsk

Sergei A. Ivanov

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: walfad@mail.ru

D. Sci. (Med.), Prof. RAS

Russian Federation, Obninsk

Zhanna V. Khailova

Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: walfad@mail.ru

Cand. Sci. (Med.)

Russian Federation, Obninsk

Tigran G. Gevorkian

Blokhin National Medical Research Center of Oncology

Email: walfad@mail.ru

Deputy Director

Russian Federation, Moscow

References

  1. Румянцев П.О., Ильин А.А., Румянцева У.В., Саенко В.А. Рак щитовидной железы: современные подходы к диагностике и лечению. М.: ГЭОТАР-Медиа, 2009.[Rumyantsev P.O., Ilyin A.A., Rumyantseva U.V., Saenko V.A. Thyroid cancer: modern approaches to diagnosis and treatment. Moscow: GEOTAR-Media, 2009 (in Russian).]
  2. Каприн А.Д., Старинский В.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ НМИРЦ Минздрава России, 2017; c. 33, 151.[Kaprin A.D., Starinskiy V.V. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Moscow: MNIOI im. P.A. Gertsena – filial FGBU NMIRTs Minzdrava Rossii, 2017; c. 33, 151 (in Russian).]
  3. Allelein S, Ehlers M, Morneau C et al. Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer. Hormone Metab Res 2017; 50 (1): 23–8.
  4. Матякин Е.Г., Подвязников С.О. Опухоли щитовидной железы. Онкология: справочник практикующего врача. Под ред. И.В. Поддубной. М.: МЕДпресс-информ, 2009; c. 177–85.[Matyakin E.G., Podvyaznikov S.O. Tumors of the thyroid gland. Oncology: a handbook of a practicing physician. Ed. I.V. Poddubnaya. Moscow: MEDpress-inform, 2009; p. 177–85 (in Russian).]
  5. Бржезовский В.Ж. Опухоли щитовидной железы. Опухоли головы и шеи. 5-е изд., доп. и перераб. М.: Практическая медицина, 2013; с. 339–59.[Brzhezovsky V.Zh. Tumors of the thyroid gland. Tumors of the head and neck. 5th ed., Add. and revised Moscow: Prakticheskaia meditsina, 2013; p. 339–59 (in Russian).]
  6. Бельцевич Д.Г., Ванушко В.Э., Румянцев П.О. и др. Российские клинические рекомендации по диагностике и лечению высокодифференцированного рака щитовидной железы у взрослых. Эндокринная хирургия. 2017; 1 (11): 6–27.[Bel’tsevich D.G., Vanushko V.E., Rumiantsev P.O. et al. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu vysokodifferentsirovannogo raka shchitovidnoi zhelezy u vzroslykh. Endokrinnaia khirurgiia. 2017; 1 (11): 6–27 (in Russian).]
  7. Алиева С.Б., Алымов Ю.В., Кропотов М.А. и др. Рак щитовидной железы. Онкология. Клинические рекомендации. Под ред. М.И. Давыдова. М.: Издательская группа РОНЦ, 2015; c. 538–47.[Alieva S.B., Alymov Yu.V., Kropotov M.A. and other Thyroid cancer. Oncology. Clinical guidelines. Ed. M.I. Davydov. Moscow: Publishing group RONTs, 2015; p. 538–47 (in Russian).]
  8. Злокачественные опухоли головы и шеи. Под ред. С.О. Подвязникова, А.М. Мудунова, М.В. Болотина и др. Клинические рекомендации по лечению опухолей головы и шеи Общенациональной онкологической сети (США). М.: АБВ-пресс, 2019.[Malignant tumors of the head and neck. Ed. S.O. Podvyaznikova, A.M. Mudunova, M.V. Bolotina et al. Clinical guidelines for the treatment of head and neck tumors from the National Cancer Network (USA). Moscow: ABV-press, 2019 (in Russian).]
  9. Онкология. Клинические рекомендации. Под ред. В.И. Чиссова. М.: ГЭОТАР-Медиа, 2006; c. 125–39.[Oncology. Clinical guidelines. Ed. IN AND. Chissova. Moscow: GEOTAR-Media, 2006; p. 125–39 (in Russian).]
  10. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109–42.
  11. McLeod DS, Watters KF, Carpenter AD et al. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 2012; 97: 2682–92. http://www.ncbi.nlm.nih.gov/pubmed/22622023
  12. Rinaldi S, Plummer M, Biessy C et al. Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. J Natl Cancer Inst 2014; 106: dju097. http://www.ncbi.nlm.nih.gov/pubmed/24824312
  13. Bonavita JA, Mayo J, Babb J et al. Pattern recognition of benign nodules at ultrasound of the thyroid: which nodules can be left alone? AJR Am J Roentgenol 2009; 193: 207–13. http://www.ncbi.nlm.nih.gov/pubmed/24824312
  14. Alexander EK, Cooper D. The importance, and important limitations, of ultrasound imaging for evaluating thyroid nodules. JAMA Intern Med 2013; 173: 1796–7. http://www.ncbi.nlm.nih.gov/pubmed/23979653
  15. Friedrich-Rust M, Meyer G, Dauth N et al. Interobserver agreement of Thyroid Imaging Reporting and Data System (TIRADS) and strain elastography for the assessment of thyroid nodules. PLoS One 2013; 8: e77927. http://www.ncbi.nlm.nih.gov/pubmed/24205031
  16. Kamran SC, Marqusee E, Kim MI et al. Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab 2013; 98: 564–70. http://www.ncbi.nlm.nih.gov/pubmed/23275525
  17. Yang J, Schnadig V, Logrono R, Wasserman PG. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer 2007; 111: 306–15. http://www.ncbi.nlm.nih.gov/pubmed/17680588
  18. Danese D, Sciacchitano S, Farsetti A et al. Diagnostic Accuracy of Conventional Versus Sonography-Guided Fine-Needle Aspiration Biopsy of Thyroid Nodules. Thyroid 1998; 8 (1): 15–21. http://www.ncbi.nlm.nih.gov/pubmed/24205031
  19. Trimboli P, D’Aurizio F, Tozzoli R, Giovanella L. Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids. Clin Chem Lab Med 2017; 55 (7). http://www.ncbi.nlm.nih.gov/pubmed/24205031
  20. Cibas ES, Ali SZ. The 2017 Bethesda System For Reporting Thyroid Cytopathology. Thyroid 2017; 27: 1341–6. http://www.ncbi.nlm.nih.gov/pubmed/29091573
  21. Pacini F, Capezzone M, Elisei R et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87: 1499–501. https://www.ncbi.nlm.nih.gov/pubmed/27581851
  22. Giordano TJ, Beaudenon-Huibregtse S, Shinde R et al. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens. Hum Pathol 2014; 45: 1339–47. http://www.ncbi.nlm.nih.gov/pubmed/24830619
  23. Nikiforov YE, Ohori NP, Hodak SP et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011; 96: 3390–7. http://www.ncbi.nlm.nih.gov/pubmed/21880806
  24. Musholt TJ, Fottner C, Weber MM et al. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg 2010; 34: 2595–603. http://www.ncbi.nlm.nih.gov/pubmed/20652698
  25. Liu R, Bishop J, Zhu G et al. Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality. JAMA Oncol 2017; 3 (2): 202–8. https://www.ncbi.nlm.nih.gov/pubmed/27581851
  26. Vuong HG, Altibi AMA, Duong UNP, Hassell L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clin Endocrinol (Oxf) 2017; 87: 411–7. https://www.ncbi.nlm.nih.gov/pubmed/28666074
  27. Bilimoria KY, Zanocco K, Sturgeon C. Impact of surgical treatment on outcomes for papillary thyroid cancer. Adv Surg 2008; 42: 1–12. http://www.ncbi.nlm.nih.gov/pubmed/18953806
  28. Hay ID, Grant CS, Bergstralh EJ et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998; 124: 958–64; discussion 964–56. http://www.ncbi.nlm.nih.gov/pubmed/9854569
  29. Dackiw AP, Zeiger M. Extent of surgery for differentiated thyroid cancer. Surg Clin North Am 2004; 84: 817–32. http://www.ncbi.nlm.nih.gov/pubmed/15145237
  30. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Thyroid Carcinoma. Version 3.2019. https://www.ncbi.nlm.nih.gov/pubmed/27581851
  31. Cady B. Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997; 174: 462–8. http://www.ncbi.nlm.nih.gov/pubmed/9374215
  32. Matsuzu K, Sugino K, Masudo K et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg 2014; 38: 68–79. http://www.ncbi.nlm.nih.gov/pubmed/24081532
  33. Udelsman R, Lakatos E, Ladenson P. Optimal surgery for papillary thyroid carcinoma. World J Surg 1996; 20: 88–93. http://www.ncbi.nlm.nih.gov/pubmed/8588420
  34. Sacks W, Fung CH, Chang JT et al. The Effectiveness of Radioactive Iodine for Treatment of Low-Risk Thyroid Cancer: A Systematic Analysis of the Peer-Reviewed Literature from 1966 to April 2008. Thyroid 2010; 20 (11): 1235–45. http://www.ncbi.nlm.nih.gov/pubmed/24081532
  35. Iyer NG, Morris LG, Tuttle RM et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011; 117: 4439–46. http://www.ncbi.nlm.nih.gov/pubmed/21432843
  36. Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope 2004; 114: 393–402. http://www.ncbi.nlm.nih.gov/pubmed/15091208
  37. Scheumann GF, Seeliger H, Musholt TJ et al. Completion thyroidectomy in 131 patients with differentiated thyroid carcinoma. Eur J Surg 1996; 162: 677–84. http://www.ncbi.nlm.nih.gov/pubmed/8908447
  38. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7: 265–71. http://www.ncbi.nlm.nih.gov/pubmed/9133698
  39. Buffet C, Ghander C, le Marois E, Leenhardt L. Indications for radioiodine administration in follicular-derived thyroid cancer. Annales d’Endocrinologie 2015; 76 (1): 1S2–1S7. doi: 10.1016/s0003-4266(16)30008-7
  40. Castagna MG, Cantara S, Pacini F. Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients. J Endocrinol Investig 2016; 39 (10): 1087–94. http://www.ncbi.nlm.nih.gov/pubmed/8908447
  41. Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010; 20: 135–46. http://www.ncbi.nlm.nih.gov/pubmed/20151821
  42. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997; 82: 3637–42. http://www.ncbi.nlm.nih.gov/pubmed/9360519
  43. Lo SS, Lutz ST et al. Expert Panel on Radiation Oncology-Bone Metastases. ACR Appropriateness Criteria (R) spinal bone metastases. J Palliat Med 2013; 16: 9–19. http://www.ncbi.nlm.nih.gov/pubmed/23167547
  44. Kebebew E, Greenspan FS, Clark OH et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005; 103: 1330–5. http://www.ncbi.nlm.nih.gov/pubmed/15739211
  45. Shaha AR. Airway management in anaplastic thyroid carcinoma. Laryngoscope 2008; 118: 1195–8. http://www.ncbi.nlm.nih.gov/pubmed/18438260
  46. Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992; 18: 83–8. http://www.ncbi.nlm.nih.gov/pubmed/1582515
  47. Smallridge RC, Ain KB, Asa SL et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012; 22: 1104–39. http://www.ncbi.nlm.nih.gov/pubmed/23130564
  48. Ernaga-Lorea A, Hernández-Morhain MC, Anda-Apiñániz E et al. Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma. Clin Translational Oncol 2017; 20 (6): 740–4. http://www.ncbi.nlm.nih.gov/pubmed/23130564
  49. Pacini F, Lari R, Mazzeo S et al. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 1985; 23: 405–11. http://www.ncbi.nlm.nih.gov/pubmed/4064348
  50. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005; 90: 5047–57. http://www.ncbi.nlm.nih.gov/pubmed/15972576
  51. Sherman SI, Tielens ET, Sostre S et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994; 78: 629–34. http://www.ncbi.nlm.nih.gov/pubmed/8126134
  52. OʼConnell TB, OʼDoherty MJ. Differentiated thyroid cancer and pregnancy. Nuclear Med Commun 2000; 21 (2): 127–8. http://www.ncbi.nlm.nih.gov/pubmed/8126134
  53. Gibelli B, Zamperini P, Proh M, Giugliano G. Management and follow-up of thyroid cancer in pregnant women. Acta Otorhinolaryngol Ital 2011; 31 (6): 358–65. https://www.ncbi.nlm.nih.gov/pubmed/22323846
  54. McDougall IR, Weigel RJ. Recombinant human thyrotropin in the management of thyroid cancer. Cur Opin Oncol 2001; 13 (1): 39–43. http://www.ncbi.nlm.nih.gov/pubmed/8908447

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Appendix B. Patient management algorithms

Download (81KB)
Indexing metadata

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies